113 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author윤채옥-
dc.date.accessioned2019-11-26T05:59:15Z-
dc.date.available2019-11-26T05:59:15Z-
dc.date.issued2017-06-
dc.identifier.citationCANCER LETTERS, v. 396, page. 155-166en_US
dc.identifier.issn0304-3835-
dc.identifier.issn1872-7980-
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S0304383517301738?via%3Dihub-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/114639-
dc.description.abstractPancreatic cancer is a highly lethal disease for which limited therapeutic options are available. Pancreatic cancer exhibits a pronounced collagen-rich stromal reaction, which induces chemoresistance by inhibiting drug diffusion into the tumor. Complementary treatment with oncolytic virus such as an oncolytic adenovirus expressing relaxin (YDC002) is an innovative treatment option for combating chemoresistant pancreatic cancer. Here, we examined the ability of combined treatment with gemcitabine and YDC002, which degrades extracellular matrix (ECM), to efficiently treat chemoresistant and desmoplastic pancreatic cancer. Gemcitabine alone exhibited similarly low cytotoxicity toward pancreatic cancer cells throughout the concentration range (1-50 mu M) used, whereas the combination of YDC002 and a sub therapeutic dose of gemcitabine (0.01-0.05 mu M) resulted in potent anticancer effects through effective induction of apoptosis. Importantly, YDC002 combined with gemcitabine significantly attenuated the expression of major ECM components including collagens, fibronectin, and elastin in tumor spheroids and xenograft tumors compared with gemcitabine alone, resulting in potent induction of apoptosis, gemcitabine-mediated cytotoxicity, and an oncolytic effect through degradation of tumor ECM. Our results demonstrate that YDC002 can selectively degrade aberrant ECM and attenuate the ECM-induced chemoresistance observed in desmoplastic pancreatic tumor, resulting in a potent antitumor effect through effective induction of apoptosis. (C) 2017 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipThis research was supported by grants from the National Research Foundation (NRF) of Korea (2015R1A2A1A10054108, 2015M3A9C407581, 2014M3C1A3051476 to S.S. Hong; 2015R1A2A1A13027811, 2016M3A9B5942352 to C.O. Yun), and a grant (HI15C0554) from the Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.en_US
dc.language.isoen_USen_US
dc.publisherELSEVIER IRELAND LTDen_US
dc.subjectAdenovirusen_US
dc.subjectRelaxinen_US
dc.subjectGemcitabineen_US
dc.subjectExtracellular matrixen_US
dc.subjectPancreatic canceren_US
dc.titleOncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic canceren_US
dc.typeArticleen_US
dc.relation.no396-
dc.relation.volume28-
dc.identifier.doi10.1016/j.canlet.2017.03.009-
dc.relation.page155-166-
dc.relation.journalCANCER LETTERS-
dc.contributor.googleauthorJung, Kyung Hee-
dc.contributor.googleauthorChoi, Il-Kyu-
dc.contributor.googleauthorLee, Hee-Seung-
dc.contributor.googleauthorYan, Hong Hua-
dc.contributor.googleauthorSon, Mi Kwon-
dc.contributor.googleauthorAhn, Hyo Min-
dc.contributor.googleauthorHong, JinWoo-
dc.contributor.googleauthorYun, Chae-Ok-
dc.contributor.googleauthorHong, Soon-Sun-
dc.relation.code2017001067-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidchaeok-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE